Pneumonia in patients with chronic kidney disease V D stage: pathogenetic aspects of complex therapy and outcomes

Keywords: chronic kidney disease, renal replacement therapy, patients, рneumonia, treatment, oxidative stress, survival


Abstract.The aim of our study was to increase the effectiveness of treatment of comorbid pneumonia in patients with CKD VD stage.

Materials and Methods. 73 patients with CKD VD st. (59 on HD and 14 on PD) with mild to moderate comorbid pneumonia who received renal replacement therapy (RRT) during 2013-2016 were included in the observational prospective open-label randomized trial. Patients were randomized into two groups: group 1 (n = 42) included patients who in addition to the conventional therapy of pneumonia received medication «Lipin» as a complex therapy; group 2 included patients (n = 31) who received only basic (traditional) therapy. The groups were representative by the main demographic, social and clinical-laboratory findings, severity of pneumonia, duration and modality of RRT. The primary endpoints were death from any cause and episodes of rehospitalization. The overall assessment of the clinical efficacy of the therapy was based on a comparison of the duration of hospitalization, antibiotic therapy, intoxication syndrome, and regression of X-ray changes.

Survival in observation groups was determined by the Kaplan-Meier method. Analyzed cases were included to October 31, 2018.

The markers of oxidative stress (OS) were determined in 29 patients of group 1 and 14 patients of group 2 before treatment and after 14 days while treatment of  pneumonia was started.

Results. The analysis demonstrated that during a 1-year period a 17 (25,76%) episodes of rehospitalization were recorded: 11 causes (35.5%) in group 1 and 6 (14.3%) in group 2 (χ² = 4.486, p = 0.035). In total, 29 deaths were recorded during the study period: 10 (23.8%) cases in group 1, and 19 (61.3%) - in group 2 (χ² = 8.957, p = 0.003, RR - 2.574, 95% CI: 1.400-4.733). The three- and five-year cumulative survival rates were 83% vs. 21% and 59% vs. 21%, in the group 1 and group 2, respectively (p = 0.00003). It was stated that the duration of hospitalization, antibiotic therapy, intoxication syndrome and X-ray regression were significantly lower in group 1 compared with group 2 (p <0.05). The comparative analysis of dynamics in the groups shows that increasing the treatment effectiveness at complex therapy background accompanied by a significant positive dynamics of OS markers (p <0,05).

Conclusions Thus, the results of this study demonstrated the effectiveness of complex method of pneumonia treatment in patients with CKD stage 5D including Lipin medication compared traditional therapy. There is a significant difference in patient survival depending on the proposed and generally accepted treatment.


Download data is not yet available.


Shifris I. M. Carriage of opportunistic microorganisms and survival of patients with chronic kidney disease stage 5 D. Ukrainian Journal of Nephrology and Dialysis. 2017; 1(53): 13-20. doi: 10.31450/ukrjnd.1(53).2017.02.

Mazonakis E, Stirling C, Booth KL, McClenahan J, Heron N, Geddes CC. The influence of comorbidity on the risk of access-related bacteremia in chronic hemodialysis patients. Hemodialysis Int. 2009;13(1):6-10. doi: 10.1111/j.1542-4758.2009.00327.x.

Shifris І., Krot V., Gonchar Y., Krasyuk E., & Dudar I. Hospital morbidity in patients with chronic kidney disease stage VD. Ukrainian Journal of Nephrology and Dialysis. 2014; 4(44): 31-40. doi: 10.31450/ukrjnd.4(44).2014.02/

Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US Renal Data System 2018 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018; 71(3)(suppl 1):1-672. doi: 10.1053/j.ajkd.2018.01.002. 16.

Scott Sibbel, Reiko Sato, Abigail Hunt, Wendy Turenne & Steven M. Brunelli. The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study. BMC Nephrology. 2016; 17(1):199. doi: org/10.1186/s12882-016-0412-6.         

Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients – The United States renal data system. Nephrol Dial Transplant. 2008; 23:680-686. doi: 10.1093/ndt/gfm474.

Trefler S., Rodríguez A., Martín-Loeches I., Sanchez V., Marín J., Llauradó M, et al.  Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot study. Med Intensiva. 2014; 38(2):73-82. doi: 10.1016/j.medin.2013.01.004.

Castillo RL, Carrasco RA, Alvarez PI, Ruiz M, Luchsinger V., Zunino E, et al.   Relationship between severity of adult community-acquired pneumonia and impairment of the antioxidant defense system. 2013;46(2):207-13. doi: 10.4067/S0716-97602013000200013.

Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006; 70: 1135–1141. doi: 10.1038/

 Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63(5): e61-e111.  doi: 10.1093/cid/ciw353.

 Liu J, Yu SB, Zeng XX, Yuan HH, Salerno S, Fu P. Clinical Characteristics of Pneumonia in Chinese Hemodialysis Patients. Chin Med J (Engl). 2018;131(4): 498-501. 498-501. doi: 10.4103/0366-6999.225046.

 Ostrovskyi M.M. Surfaktantna systema lehen pry zatiazhnykh pnevmoniiakh ta shliakhy optymizatsii yii medykamentoznoi korektsii. Halytskyi likarskyi visnyk. 2003; 3: 61-65.  [In Ukrainian]

 Chernyi  V. Y., Kardash A. M., Horodnyk H. A., Popovskyi D. L., Stoichev A. K.   Lechenye bronkhopnevmonyi u bolnыkh s tiazheloi cherepno-mozghovoi travmoi. Ukrainskyi neirokhirurhichnyi zhurnal. 2000;  3: 20-25. [In Ukrainian]. Available from:

 Kovalenko V. M. Terapevtychnyy potentsial ta mekhanizmy diyi fosfolipidnykh liposom. Farmakolohiya ta likarsʹka toksykolohiya. 2016; 3 (49):91-98. [In Ukrainian]. Available from:

 Guidelines for the management of community acquired pneumonia in adults: update 2009 British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group. Thorax. 2009; Vol 64 Supplement III:iii1–iii55. doi: 10.1136/thx.2009.121434.

Feshchenko, Yu. I., Holubovs'ka, O. A., Honcharov, K. A., Dzyublyk, O. Ya., Dzyublyk, Ya. O., Dmytrychenko, V. V. et. al.. Community-acquired pneumonia in adults: etiology, pathogenesis, classification, diagnosis, antibiotic therapy (draft clinical guidelines). Ukrainian Pulmonology Journal. 2012; 4: 5–17. [In Ukrainian]. Available from:

 Korol LV, Myhal LIa, Dudar IO, Shifris IM, vynakhidnyky; DU "In-t nefrolohii AMN Ukrainy", patentovlasnyk. Sposib otsinky efektyvnosti korektsii antyoksydantnoi yemnosti syrovatky krovi u khvorykh na khronichnu khvorobu nyrok VD stadii. Patent Ukrainy. № 119038. 2017  Lystop. 09. [In Ukrainian].

 Jeff S. Coombes and Robert G. Fassett. Antioxidant therapy in hemodialysis patients: a systematic review. Kidney International. 2012; 81: 233–246. doi: 10.1038/ki.2011.341

Abstract views: 44
PDF Downloads: 35
How to Cite
Shifris, I., Korol, L., Magas, O., Krasiuk, E., & Dudar, I. (2019). Pneumonia in patients with chronic kidney disease V D stage: pathogenetic aspects of complex therapy and outcomes. Ukrainian Journal of Nephrology and Dialysis, (1(61), 20-28.

Most read articles by the same author(s)

1 2 > >>